Global Neuroendocrine Tumors (NETs) Epidemiology Forecast to 2027, Covering the U.S., EU5 & Japanese Markets - ResearchAndMarkets.com

DUBLIN--()--The "Neuroendocrine Tumors (NETs) - Epidemiology Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, total incident cases, diagnosed prevalent cases, symptom based classification of NETs (asymptomatic and symptomatic), diagnosed prevalence based on malignancy (Malignant and non-malignant), site specific incident cases (Gastroenteropancreatic, lung and other sites), Grade-wise prevalent cases (Grade I, Grade II and Grade III) and stage-wise prevalent cases (localized, regional and distant) scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this research, the total prevalent population of Neuroendocrine Tumors (NETs) was found to be 442,100 in the year 2016 in 7MM.

Report Scope:

  • The report covers detailed overview of Neuroendocrine Tumors explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Neuroendocrine Tumors in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by symptoms, malignancy, site-specific, stage-wise and grade-wise population of NETs in 7MM

Key assessments:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Key Topics Covered:

1. Key Insights

2. Disease Background and Overview: Neuroendocrine Tumors (NETs)

3. Epidemiology and Patient Population

4. Appendix

5. Capabilities

6. Disclaimer

7. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/research/m5q2lr/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs